3033-55-4

Basic information

• Product Name: trans-(+/-)-2-Phenylcyclopentan-3-one-1-carboxylic acid
• CAS NO: 3033-55-4
• Molecular Weight: 204.225
• Mol File: 3033-55-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: trans-(+/-)-2-Phenylcyclopentan-3-one-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: trans-(+/-)-2-Phenylcyclopentan-3-one-1-carboxylic acid(3033-55-4)
• EPA Substance Registry System: trans-(+/-)-2-Phenylcyclopentan-3-one-1-carboxylic acid(3033-55-4)

Safety Data

• Hazardous Substances Data: 3033-55-4(Hazardous Substances Data)

Upstream product

• 100-52-7 benzaldehyde 
• 2025-40-3 ethyl benzylidenecyanoacetate 
• 873380-10-0 2-cyano-2-(cyano-phenyl-methyl)-glutaric acid diethyl ester 
• 190269-54-6 1-phenyl-butane-1,2,4-tricarboxylic acid trimethyl ester 
• 190271-89-7 1-phenyl-butane-1,2,4-tricarboxylic acid 
• 5473-13-2 ethyl 2,3-dicyano-3-phenylpropanoate 
• 859317-18-3 4-oxo-5-phenyl-cyclopentane-1,3-dicarboxylic acid dimethyl ester 

Downstream Products

• 854419-10-6 (3-ethoxycarbonyl-1-hydroxy-2-phenyl-cyclopentyl)-acetic acid ethyl ester 
• 1198-34-1 2-Phenylcyclopentanone 
• 909784-70-9 [(1S,2R,3R)-3-(3,5-Bis-trifluoromethyl-benzyloxy)-2-phenyl-cyclopentyl]-carbamic acid (S)-1-phenyl-ethyl ester 
• 909784-71-0 [(1R,2S,3S)-3-(3,5-Bis-trifluoromethyl-benzyloxy)-2-phenyl-cyclopentyl]-carbamic acid (S)-1-phenyl-ethyl ester 

Relevant articles and documents

Cyclopentane-based human NK1 antagonists. Part 1: Discovery and initial SAR

An initial investigation of the novel cyclopentane scaffold 6 afforded low nanomolar human NK1 antagonists having enhanced water solubility properties compared to morpholine 1. A synthesis of this cyclopentane scaffold, having three contiguous chiral cent

Phenyl spiroethercycloalkyl tachykinin receptor antagonists

The present invention is directed to certain novel compounds represented by structural formula I: STR1 or a pharmaceutically acceptable salt thereof, wherein R 3, R 6, R 7, R 8, R 11, R 12, R 13, m, n and the dashed lines are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.

CYCLOALKYL TACHYKININ RECEPTOR ANTAGONISTS

-